Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?

Garassino MC, Farina G, Rossi A, Martelli O, Torri V. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab? J Clin Oncol. 2008 May 20; 26(15):2600; author reply 2601-2.

View in: PubMed

collapse authors with profiles